PATENT 89188.0022

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Shi-Lung Lin et al.

Serial No: 09/920,342

Filed: August 1, 2001

GENE SILENCING USING MRNA-CDNA

HYBRIDS

VERIFIED STATEMENT UNDER 37 C.F.R. §1.821(f)

Mail Stop Sequence Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

I, Yanan Luo, declare that I personally prepared the paper and the computerreadable copy of the substitute Sequence Listing filed herewith for the aboveidentified application and that the content of both is the same.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of The United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Dated: February 13, 2004

Bv: Yanan Luo

Reg. No. 54,284

Art Unit: 1635

Examiner: Karen A. Lacourciere

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed

Mail Stop Sequence Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450 on

February 13, 2004 Date of Deposit

Vivian Gutierrez

Signature

02/13/2004

oplication Serial No. 09/920,342

PATENT 89188.0022

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Shi-Lung Lin et al.

Serial No: 09/920,342

Filed: August 1, 2001

For: GENE SILENCING USING MRNA-CDNA

HYBRIDS

SUBMISSION OF SUBSTITUTE

SEQUENCE LISTING

Mail Stop Sequence Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed are a computer readable disk copy of the substitute sequence listing, a copy of the substitute sequence listing, and a verified statement concerning sequence listing. Applicants' undersigned representative hereby states that the information recorded in the computer readable form is identical to the written

Respectfully submitted.

HOGAN & HARTSON L.L.P.

Dated: February 13, 2004

Yanan Luo Reg. No. 54,284

Biltmore Tower 500 South Grand Avenue, Suite 1900 Los Angeles, CA 90071

Telephone: (213) 337-6700

Fax: (213) 337-6701

sequence listing.

\\LA - 89188/0022 - 193187 v1

Art Unit: 1635

Examiner: Karen A. Lacourciere

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Sequence Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450 on

February 13, 2004 Date of Deposit

Signature,

Application No.: 09/9	20.342
-----------------------	--------

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	 This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 11 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemakin notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). 	114
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).	9
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).	y _
X	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached letter to Complywith the sequence Rules.	
	5. The computer readable form that has been filed with this application has been found to be damage and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).	ed ·
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).	
	7. Other:	
Apı	plicant Must Provide:	
X	An initial or <u>substitute</u> computer readable form (CRF) copy of the "Sequence Listing".	
X	An initial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its en into the specification.	ntry
ت	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).	
For	r questions regarding compliance to these requirements, please contact:	
For	r Rules Interpretation, call (703) 308-4216 r CRF Submission Help, call (703) 308-4212 tentln Software Program Support	

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

Technical Assistance......703-287-0200 To Purchase PatentIn Software.....703-306-2600